IntrinsicIntrinsic
← All summaries

AI Financial Corp

ALTS
Financials & Chart →

Business Summary

ALT5 Sigma Corporation operates in the financial technology (Fintech) industry, providing blockchain-powered technologies for digital asset trading, payments processing, and related payment card services . The company also has a Biotechnology segment focused on developing non-opioid pain and addiction therapies, which is currently presented as a discontinued operation . The global digital assets market experienced substantial growth in 2024, with its market capitalization nearly doubling to approximately $3.91 trillion by mid-December, before consolidating at $3.0 trillion . Bitcoin continues to lead this market, maintaining a significant share of the total market capitalization . The global payments industry revenue reached $2.5 trillion in 2025, with projections to reach $2.7 trillion in 2026 at an annualized growth rate of 7% . Specifically, the crypto payment gateway market size is expected to reach $3.5 billion by 2030, growing at a CAGR of 15.6% from $1.5 billion in 2024 .

The company's competitive advantage in the digital assets market for its ALT5 Prime, ALT5 Pay, and StrataCarte products and services is stated to be its interface, speed, customer service, and feature set, which are aimed at the business-to-business (B2B) market, enabling a tailored product offering . The company also offers a white-label product that can be seamlessly integrated with a customer's existing systems . The company's main target market and focus are FINRA-registered broker-dealers, banks, and global merchants . According to FINRA, there are 3,249 broker-dealers registered and under supervision, representing approximately 628,000 registered representatives .

ALT5 Sigma Corporation generates revenue through initial installation or setup fees, monthly maintenance fees, spreads, and transaction commission fees . Transaction fees range from 0.25% to 5% on all transactions, including buy, sell, or payment processing, depending on the industry and volume . The company's primary customer segments include banks, broker-dealers, funds, family offices, proprietary trading firms, liquidity providers, financial information providers, payment processing partners, and merchants . As of December 27, 2025, the company has approximately 1,900 corporate customers located in 50 countries .

The Fintech segment offers three main platforms: ALT5 Pay, ALT5 Prime, and StrataCarte . ALT5 Pay is a cryptocurrency payment gateway enabling global merchants to accept and make cryptocurrency payments or integrate the platform using plugins, checkout widgets, and APIs . Merchants can convert to fiat currency (U.S. Dollars, Canadian Dollars, Euros, and British Pounds Sterling) automatically or receive digital assets . ALT5 Prime is an electronic over-the-counter trading platform for registered customers to buy and sell digital assets with fiat currencies (US dollars, Canadian dollars, Euros, and British Pounds) . It is accessible via a browser-based application, a mobile app "ALT5 Pro," and through Broadridge Financial Solutions' NYFIX gateway . StrataCarte, acquired on May 9, 2025, is a payment solutions provider offering multi-currency, fiat payment card services with crypto-enabled capabilities through its integration with the ALT5 Subsidiary platform . It provides physical and virtual cards on Visa and Mastercard networks for spending traditional and digital currencies worldwide . The Biotechnology segment, now a discontinued operation, holds clinical-stage biopharmaceutical assets focused on novel, non-opioid, and non-addictive therapies for pain and addiction . JAN101 is a potential treatment for PAD, with Phase IIb/III clinical trials expected to commence in 2026 . JAN123 is a novel formulation of Low-dose naltrexone (LDN) for Complex Regional Pain Syndrome (CRPS) .

For the fiscal year ended December 27, 2025, total revenue was $24,840 thousand . Cost of revenue was $14,652 thousand , resulting in a gross profit of $10,188 thousand and a gross margin of 41% . Operating loss was $22,851 thousand . Net loss before provision for income taxes was $428,228 thousand . Income tax benefit was $86,742 thousand , leading to a net loss from continuing operations of $341,486 thousand . Loss from discontinued operations was $3,898 thousand , with an income tax benefit from discontinued operations of $877 thousand , resulting in a net loss from discontinued operations of $3,021 thousand . The total net loss for the period was $344,507 thousand . Basic and diluted EPS from continuing operations was $(5.86) , and total basic and diluted EPS was $(5.91) . As of December 27, 2025, cash and cash equivalents were $6,222 thousand . Total current assets were $29,466 thousand , and total current liabilities were $51,399 thousand , resulting in a net negative working capital of $21,933 thousand . Total debt, including convertible debentures and notes payable, was $15,260 thousand . The company held cryptocurrency assets at fair value of $1,054,663 thousand .

Revenue increased by approximately $13.0 million for the fiscal year ended December 27, 2025, compared to the year ended December 28, 2024 . This increase was due to the acquisition of ALT5 Subsidiary in May 2024 and Mswipe in May 2025 . Gross profit increased by approximately $4.6 million for the same period, also attributed to these acquisitions . The gross profit percentage for the Fintech segment decreased from 47.5% in fiscal year ended December 28, 2024 to 41.0% in fiscal year ended December 27, 2025 . Selling, general and administrative expenses from continuing operations increased by approximately $20.5 million , primarily due to the acquisitions, higher bad debt and legal expenses, and increased stock-based compensation . Interest expense, net, increased from approximately $1.2 million in fiscal 2024 to approximately $3.9 million in fiscal 2025 , driven by the ALT5 Subsidiary acquisition and higher average debt balances . An unrealized loss on cryptocurrency assets of approximately $402.0 million was recorded in fiscal 2025 to mark WLFI tokens to fair value, with no such loss in fiscal 2024 .

During fiscal year 2025, the company acquired Fortress II Holdings Ltd. d/b/a Mswipe on May 9, 2025 , a payment solutions provider offering multi-currency, fiat payment card services with crypto-enabled capabilities . In August 2025, the company closed a $1.5 billion registered direct offering and concurrent private placement, led by World Liberty Financial, Inc., to support its WLFI Treasury Strategy, acquiring a significant position in WLFI tokens . The company also announced its intent to formally separate its Biotechnology segment, Alyea Therapeutics Corporation, into a separate company .

Business Outlook

The company intends to raise funds to support future development of JAN123 in its Biotechnology segment either through capital raises or structured arrangements, which would include capitalizing a subsidiary with certain biotechnology assets, acquiring an additional biotechnology asset, and then engaging in a financing of that subsidiary . The short-term intended result of that series of transactions would be for the company to own a controlling interest in that subsidiary, but to decouple it so that it would operate on a stand-alone basis, although its financial statements would continue to be consolidated .

The company's policy remains a committed long-term approach, with future acquisitions funded through operating cash flows, structured debt, and selective capital raises . Sales of WLFI tokens are restricted to liquidity requirements or material portfolio rebalancing events . The company intends to integrate WLFI into its existing payment and trading infrastructure, which serves clients in North America, Europe, and Asia . The vision includes collaborating with WLFI to help enable everyday commerce, such as retailers accepting WLFI or USD1 with instant fiat conversion, cross-border B2B settlements, and tokenized assets settled using WLFI and/or USD1 as the medium of exchange .

The company is in the process of developing a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of its critical systems and information . This program is being evaluated for alignment with the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF) and is intended to be integrated into the overall enterprise risk management (ERM) program . The company is evaluating the development of processes to maintain an inventory of information assets, systems, and data, and to conduct periodic cybersecurity risk assessments . Management is evaluating potential remediation measures and enhancements to its cybersecurity risk management program for future implementation on a prioritized basis, including the possible engagement of third-party resources . The company is also reviewing the adoption of a defense-in-depth security architecture to protect its systems, data, and customer assets, with technical and administrative controls under evaluation for future implementation . No formal implementation of these controls has occurred to date, but the company intends to prioritize and implement them on a phased basis . The company is evaluating the engagement of a managed 24/7 Security Operations Center (SOC) to provide continuous threat monitoring . A written cybersecurity incident response plan (IRP) is in development to provide a structured approach to detecting, containing, eradicating, and recovering from cybersecurity incidents . No formal training program has been implemented to date, but the company intends to require all employees to complete cybersecurity awareness training annually . A formal third-party risk management program is also under evaluation .

The company intends to use the proceeds from the $15.0 million loan drawn on January 29, 2026, to fund a share repurchase program as approved by the Board of Directors, to acquire additional WLFI tokens, and for general corporate purposes .

Risk Factors

The company faces several material risks, including material weaknesses in internal control over financial reporting, which could lead to inaccurate or untimely financial reporting and impact Nasdaq listing requirements . Adverse economic conditions and volatility in crypto asset markets could reduce transaction volumes, customer activity, and access to banking and capital, negatively affecting the business . The company may require additional capital for business growth, which might not be available on favorable terms, leading to potential dilution for stockholders if additional equity is issued or restrictive covenants if debt is incurred . Operations in multiple foreign jurisdictions expose the company to political, regulatory, legal, and currency risks . The highly volatile nature of crypto assets causes significant fluctuations in operating results, making accurate forecasting difficult . The company's total fintech revenue is substantially dependent on transaction volume, and a decline in volume would adversely affect the business . Cyberattacks and security breaches could harm the brand, reputation, and financial condition . The loss or destruction of private keys required to access digital assets could result in permanent, irrecoverable loss . The extensive, highly-evolving, and uncertain regulatory landscape for crypto assets, including potential classification of certain crypto assets as securities, could require significant restructuring and lead to penalties . Evolving tax treatment of digital assets creates uncertainty in tax obligations and potential retroactive liabilities . Risks from blockchain forks and the decentralized nature of blockchain protocols could disrupt platform operations and compromise network integrity . The platform is exposed to chargeback, fraud, and unauthorized transaction losses, particularly with payment card services . Customer crypto assets held on the platform are not insured by the FDIC or SIPC, exposing customers to losses in case of platform failure . Disruption of banking and financial institution relationships could materially adversely affect the ability to operate . The company is subject to extensive anti-money laundering, counter-terrorism financing, know-your-customer, and economic sanctions obligations, with non-compliance leading to significant penalties . Regulatory and market focus on climate-related risks and the environmental impact of digital asset networks may impose additional compliance costs and reputational risks . Significant disruptions in products, services, IT systems, or blockchain networks could result in customer or fund loss . Failure to retain existing customers or attract new ones, or decreased customer engagement, could significantly harm the business . Intense competition from larger crypto platforms, decentralized networks, and traditional financial institutions could reduce market share and compress margins . Risks are associated with compliance and risk management methods, which may not adequately prevent losses . The company obtains, processes, and stores sensitive personal and financial data, and failure to protect this data or comply with evolving privacy laws could adversely affect the business . Inability to protect intellectual property rights could adversely affect the business . The loss of key personnel or failure to attract and retain highly qualified personnel could adversely affect the business . The acquisition of Fortress II Holdings and its Mswipe payment card operations exposes the company to integration, compliance, and operational risks specific to the payments industry . The planned formal separation of the biotechnology segment may be unable to be effectuated, or if separated, may face challenges in raising capital or maintaining exchange listing, and could have adverse tax consequences . The market price of common stock has been, and may continue to be, volatile, leading to substantial losses for investors . Sales or distribution of substantial amounts of common stock, or the perception thereof, could cause the market price to decline .

Management Priorities

Management acknowledges the challenging competitive environment and emphasizes a focus on overall profitability, including managing expenses . The company reported a net loss from continuing operations of approximately $341.5 million for the fiscal year ended December 27, 2025, and a net loss from continuing operations of approximately $8.3 million for the fiscal year ended December 28, 2024. Management believes that the company's holdings of approximately 7.3 billion WLFI tokens, carried at a fair value of approximately $1.05 billion as of December 27, 2025, represent a significant financial resource to support liquidity . The company intends to use proceeds from a recent $15.0 million loan for a stock repurchase program, purchases of WLFI tokens, and general corporate purposes . Strategic priorities include managing liquidity, achieving revenue growth in the Fintech segment, and, if necessary, raising additional capital through debt or equity financing .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — General
  2. [2] Item 1, Business — General
  3. [3] Item 1, Business — Market Size
  4. [4] Item 1, Business — Market Size
  5. [5] Item 1, Business — Market Size
  6. [6] Item 1, Business — Market Size
  7. [7] Item 1, Business — Competition
  8. [8] Item 1, Business — Competition
  9. [9] Item 1, Business — Market Size
  10. [10] Item 1, Business — Market Size
  11. [11] Item 1, Business — Business Model/Revenue Model
  12. [12] Item 1, Business — Revenue Model
  13. [13] Item 1, Business — Our Clients
  14. [14] Item 1, Business — Our Clients
  15. [15] Item 1, Business — Fintech — Overview
  16. [16] Item 1, Business — Fintech — Overview
  17. [17] Item 1, Business — Fintech — Overview
  18. [18] Item 1, Business — Product Overview — ALT5 Prime
  19. [19] Item 1, Business — Product Overview — ALT5 Prime
  20. [20] Item 1, Business — General
  21. [21] Item 1, Business — General
  22. [22] Item 1, Business — Biotechnology — Overview
  23. [23] Item 1, Business — Biotechnology — Overview
  24. [24] Item 1, Business — Biotechnology — Overview
  25. [25] Item 7, MD&A — Results of Operations
  26. [26] Item 7, MD&A — Results of Operations
  27. [27] Item 7, MD&A — Results of Operations
  28. [28] Item 7, MD&A — Results of Operations
  29. [29] Item 7, MD&A — Results of Operations
  30. [30] Item 7, MD&A — Results of Operations
  31. [31] Item 7, MD&A — Results of Operations
  32. [32] Item 7, MD&A — Results of Operations
  33. [33] Item 7, MD&A — Results of Operations
  34. [34] Item 7, MD&A — Results of Operations
  35. [35] Item 7, MD&A — Results of Operations
  36. [36] Item 7, MD&A — Results of Operations
  37. [37] Item 7, MD&A — Results of Operations
  38. [38] Item 7, MD&A — Results of Operations
  39. [39] Item 7, MD&A — Liquidity and Capital Resources
  40. [40] Item 7, MD&A — Sources of Liquidity
  41. [41] Item 7, MD&A — Sources of Liquidity
  42. [42] Item 7, MD&A — Sources of Liquidity
  43. [43] Item 7, MD&A — Liquidity and Capital Resources
  44. [44] Item 7, MD&A — Corporate and Other
  45. [45] Item 7, MD&A — Revenue
  46. [46] Item 7, MD&A — Revenue
  47. [47] Item 7, MD&A — Gross Profit
  48. [48] Item 7, MD&A — Gross Profit
  49. [49] Item 7, MD&A — Results of Operations
  50. [50] Item 7, MD&A — Results of Operations
  51. [51] Item 7, MD&A — Selling, General and Administrative Expense
  52. [52] Item 7, MD&A — Selling, General and Administrative Expense
  53. [53] Item 7, MD&A — Interest Expense, net
  54. [54] Item 7, MD&A — Interest Expense, net
  55. [55] Item 7, MD&A — Interest Expense, net
  56. [56] Item 7, MD&A — Unrealized Loss on Cryptocurrency Assets
  57. [57] Item 7, MD&A — Unrealized Loss on Cryptocurrency Assets
  58. [58] Item 1, Business — General
  59. [59] Item 1, Business — General
  60. [60] Item 7, MD&A — Corporate and Other
  61. [61] Item 1, Business — Biotechnology — Overview
  62. [62] Item 7, MD&A — Liquidity and Capital Resources
  63. [63] Item 7, MD&A — Liquidity and Capital Resources
  64. [64] Item 7, MD&A — Corporate and Other
  65. [65] Item 7, MD&A — Corporate and Other
  66. [66] Item 7, MD&A — Corporate and Other
  67. [67] Item 7, MD&A — Corporate and Other
  68. [68] Item 1C, Cybersecurity — Cybersecurity Risk Management and Strategy
  69. [69] Item 1C, Cybersecurity — Cybersecurity Risk Management and Strategy
  70. [70] Item 1C, Cybersecurity — Cybersecurity Risk Management and Strategy
  71. [71] Item 1C, Cybersecurity — Cybersecurity Risk Management and Strategy
  72. [72] Item 1C, Cybersecurity — Cybersecurity Risk Management and Strategy
  73. [73] Item 1C, Cybersecurity — Cybersecurity Risk Management and Strategy
  74. [74] Item 1C, Cybersecurity — Cybersecurity Risk Management and Strategy
  75. [75] Item 1C, Cybersecurity — Cybersecurity Risk Management and Strategy
  76. [76] Item 1C, Cybersecurity — Cybersecurity Risk Management and Strategy
  77. [77] Item 1C, Cybersecurity — Cybersecurity Risk Management and Strategy
  78. [78] Item 1, Note 1 — Liquidity and Going Concern Considerations
  79. [79] Item 1A, Risk Factors — Risks Relating to Our Business Generally
  80. [80] Item 1A, Risk Factors — Risks Relating to Our Business Generally
  81. [81] Item 1A, Risk Factors — Risks Relating to Our Business Generally
  82. [82] Item 1A, Risk Factors — Risks Relating to Our Business Generally
  83. [83] Item 1A, Risk Factors — Risks Relating to Our Fintech Segment
  84. [84] Item 1A, Risk Factors — Risks Relating to Our Fintech Segment
  85. [85] Item 1A, Risk Factors — Risks Relating to Our Fintech Segment
  86. [86] Item 1A, Risk Factors — Risks Relating to Our Fintech Segment
  87. [87] Item 1A, Risk Factors — Risks Relating to Our Fintech Segment
  88. [88] Item 1A, Risk Factors — Risks Relating to Our Fintech Segment
  89. [89] Item 1A, Risk Factors — Risks Relating to Our Fintech Segment
  90. [90] Item 1A, Risk Factors — Risks Relating to Our Fintech Segment
  91. [91] Item 1A, Risk Factors — Risks Relating to Our Fintech Segment
  92. [92] Item 1A, Risk Factors — Risks Relating to Our Fintech Segment
  93. [93] Item 1A, Risk Factors — Risks Relating to Our Fintech Segment
  94. [94] Item 1A, Risk Factors — Risks Relating to Our Fintech Segment
  95. [95] Item 1A, Risk Factors — Risks Relating to Our Fintech Segment
  96. [96] Item 1A, Risk Factors — Risks Relating to Our Fintech Segment
  97. [97] Item 1A, Risk Factors — Risks Relating to Our Fintech Segment
  98. [98] Item 1A, Risk Factors — Risks Relating to Our Fintech Segment
  99. [99] Item 1A, Risk Factors — Risks Relating to Our Fintech Segment
  100. [100] Item 1A, Risk Factors — Risks Relating to Our Fintech Segment
  101. [101] Item 1A, Risk Factors — Risks Relating to Our Fintech Segment
  102. [102] Item 1A, Risk Factors — Risks Relating to Our Fintech Segment
  103. [103] Item 1A, Risk Factors — Risks Relating to Our Biotechnology Segment
  104. [104] Item 1A, Risk Factors — Risks Relating to Ownership of Our Common Stock
  105. [105] Item 1A, Risk Factors — Risks Relating to Ownership of Our Common Stock
  106. [106] Item 7, MD&A — Sources of Liquidity
  107. [107] Item 7, MD&A — Sources of Liquidity
  108. [108] Item 7, MD&A — Sources of Liquidity
  109. [109] Item 1, Note 1 — Liquidity and Going Concern Considerations
  110. [110] Item 1, Note 1 — Liquidity and Going Concern Considerations
  111. [111] Item 1, Note 1 — Liquidity and Going Concern Considerations
  112. [112] Item 1, Note 1 — Liquidity and Going Concern Considerations
  113. [113] Item 1, Note 1 — Liquidity and Going Concern Considerations

Analysis on 5/19/2026